Ashish M. Kamat
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Ashish M. Kamat
Jun 8, 2024, 17:22 |
Blog
Roger Li: Final results of CORE001 trial at Nature Medicine
Roger Li, Urologic oncologist at Moffitt Cancer Center, shared on X/Twitter: "Final results of CORE001 trial…
Jun 5, 2024, 12:15 |
Societies
Ashish M. Kamat: The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer
Ashish M. Kamat, Endowed Professor of Urologic Oncology at MD Anderson Cancer Centre, shared on…
May 14, 2024, 02:29 |
Blog
Shilpa Gupta: Honored to be panel member for this highly productive San Raffaele Hospital retreat with esteemed experts!
Shilpa Gupta, Director GU Oncology at Cleveland Clinic MD, shared a post by Andrea Necchi, Associate Professor…
May 13, 2024, 08:04 |
Insight
Petros Grivas: We are getting ready for annual bladder cancer walk in Seattle Lake Sammamish
Petros Grivas, GU oncologist at Fred Hutchinson Cancer Center and Director of the University of Washington…
May 10, 2024, 12:13 |
Blog
Chiara Mercinelli: What a stimulating session on Urothelial Carcinoma with top experts!
Chiara Mercinelli, Fellow Research GU-Oncology Resident at IRCCS San Raffaele Hospital, shared a post by UroToday.com, on X: …
May 1, 2024, 08:57 |
Blog
Shilpa Gupta: Looking forward to debate session in bladder cancer
Shilpa Gupta, Director GU Oncology at Cleveland Clinic MD, shared a post by Ashish M.…
Nov 23, 2023, 16:04 |
Blog
Ashish M. Kamat: Our collaborative review on Lymph Node Dissection in GU cancers
Ashish M. Kamat, Professor of Urologic Oncology (Surgery) and Cancer Research at M.D. Anderson Cancer…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube